Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Update

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 8,600 shares, a growth of 230.8% from the December 15th total of 2,600 shares. Based on an average trading volume of 362,400 shares, the days-to-cover ratio is currently 0.0 days.

Oncotelic Therapeutics Price Performance

OTLC traded up $0.00 on Thursday, reaching $0.03. The company had a trading volume of 3,011 shares, compared to its average volume of 217,291. The company has a market capitalization of $14.14 million, a P/E ratio of -3.48 and a beta of -0.27. The company has a current ratio of 0.01, a quick ratio of 0.01 and a debt-to-equity ratio of 0.28. The company has a fifty day moving average of $0.03 and a 200-day moving average of $0.03. Oncotelic Therapeutics has a one year low of $0.02 and a one year high of $0.05.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.